1
|
Parallel Reaction Monitoring Mode for Atenolol Quantification in Dried Plasma Spots by Liquid Chromatography Coupled with High-Resolution Mass Spectrometry. Processes (Basel) 2022. [DOI: 10.3390/pr10071240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
In this study, we reported a rapid, sensitive, robust, and validated method for atenolol quantification in dried plasma spots (DPS) by liquid chromatography with high-resolution mass spectrometry (LC-HRMS) using parallel reaction monitoring mode (PRM). Aliquots of 25 µL human plasma were placed onto Whatman 903 Cards and air-dried. Disks (3.2 mm internal diameter) were punched, and a 100 µL working internal standard solution was added to each sample and then incubated on a shaker for 15 min at 40 °C, followed by rapid centrifugation (10,000× g, 10 s). The supernatant was transferred into 300 µL vials for subsequent LC–HRMS analysis. After chromatographic separation, atenolol and the internal standard were quantified in positive-ion parallel reaction monitoring mode by detection of all target product ions at 10 ppm tolerances. The total time of the analysis was 5 min. The calibration curve was linear in the range of 5–1000 ng/mL with interday and intraday precision levels and biases of <14.4%, and recovery was 62.9–81.0%. The atenolol in DPS was stable for ≥30 days at 25 and 4 °C. This fully validated method is selective and suitable for atenolol quantitation in DPS using LC–HRMS.
Collapse
|
2
|
Yi M, Sheng Q, Sui Q, Lu H. β-blockers in the environment: Distribution, transformation, and ecotoxicity. ENVIRONMENTAL POLLUTION (BARKING, ESSEX : 1987) 2020; 266:115269. [PMID: 32836046 DOI: 10.1016/j.envpol.2020.115269] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/02/2020] [Revised: 06/30/2020] [Accepted: 07/17/2020] [Indexed: 06/11/2023]
Abstract
β-blockers are a class of medications widely used to treat cardiovascular disorders, including abnormal heart rhythms, high blood pressure, and angina pectoris. The prevalence of β-blockers has generated a widespread concern on their potential chronic toxicity on aquatic organisms, highlighting the necessity of comprehensive studies on their environmental distribution, fate, and toxicity. This review summarizes the up-to-date knowledge on the source, global distribution, analytical methods, transformation, and toxicity of β-blockers. Twelve β-blockers have been detected in various environmental matrices, displaying significant temporal and spatial variations. β-blockers can be reduced by 0-99% at wastewater treatment plants, where secondary processes contribute to the majority of removal. Advanced oxidation processes, e.g., photocatalysis and combined UV/persulfate can transform β-blockers more rapidly and completely than conventional wastewater treatment processes, but the transformation products could be more toxic than the parent compounds. Propranolol, especially its (S)-enantiomer, exhibits the highest toxicity among all β-blockers. Future research towards improved detection methods, more efficient and cost-effective removal techniques, and more accurate toxicity assessment is needed to prioritize β-blockers for environmental monitoring and control worldwide.
Collapse
Affiliation(s)
- Ming Yi
- Key Laboratory of Environment Remediation and Ecological Health, Ministry of Education, College of Environmental Resource Sciences, Zhejiang University, Hangzhou, 310058, China
| | - Qi Sheng
- Key Laboratory of Environment Remediation and Ecological Health, Ministry of Education, College of Environmental Resource Sciences, Zhejiang University, Hangzhou, 310058, China
| | - Qian Sui
- State Environmental Protection Key Laboratory of Environmental Risk Assessment and Control on Chemical Process, East China University of Science and Technology, Shanghai, 200237, China
| | - Huijie Lu
- Key Laboratory of Environment Remediation and Ecological Health, Ministry of Education, College of Environmental Resource Sciences, Zhejiang University, Hangzhou, 310058, China.
| |
Collapse
|
3
|
Burt T, Young G, Lee W, Kusuhara H, Langer O, Rowland M, Sugiyama Y. Phase 0/microdosing approaches: time for mainstream application in drug development? Nat Rev Drug Discov 2020; 19:801-818. [PMID: 32901140 DOI: 10.1038/s41573-020-0080-x] [Citation(s) in RCA: 43] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/13/2020] [Indexed: 12/13/2022]
Abstract
Phase 0 approaches - which include microdosing - evaluate subtherapeutic exposures of new drugs in first-in-human studies known as exploratory clinical trials. Recent progress extends phase 0 benefits beyond assessment of pharmacokinetics to include understanding of mechanism of action and pharmacodynamics. Phase 0 approaches have the potential to improve preclinical candidate selection and enable safer, cheaper, quicker and more informed developmental decisions. Here, we discuss phase 0 methods and applications, highlight their advantages over traditional strategies and address concerns related to extrapolation and developmental timelines. Although challenges remain, we propose that phase 0 approaches be at least considered for application in most drug development scenarios.
Collapse
Affiliation(s)
- Tal Burt
- Burt Consultancy LLC. talburtmd.com, New York, NY, USA. .,Phase-0/Microdosing Network. Phase-0Microdosing.org, New York, NY, USA.
| | - Graeme Young
- GlaxoSmithKline Research and Development Ltd, Ware, UK
| | - Wooin Lee
- Seoul National University, Seoul, Republic of Korea
| | | | - Oliver Langer
- Medical University of Vienna, Vienna, Austria.,AIT Austrian Institute of Technology GmbH, Vienna, Austria
| | | | | |
Collapse
|
4
|
Devalapalli MMR, Cheruvu HS, Yertha T, Veeravalli VB, Sampathi S, Shivakumar S. Hansen solubility parameters for assay method optimization of simvastatin, ramipril, atenolol, hydrochlorothiazide and aspirin in human plasma using liquid chromatography with tandem mass spectrometry. J Sep Sci 2017; 40:3662-3674. [PMID: 28722356 DOI: 10.1002/jssc.201700565] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2017] [Revised: 07/12/2017] [Accepted: 07/12/2017] [Indexed: 11/07/2022]
Abstract
A simple, specific, sensitive, validated method was developed using liquid chromatography with tandem mass spectrometry with electrospray ionization of human plasma for the simultaneous estimation of drugs (simvastatin, ramipril, atenolol, hydrochlorothiazide, and aspirin) of PolycapTM capsule used in cardiovascular therapy. The interaction of these actives including internal standards between the stationary and mobile phase were investigated using Hansen solubility parameters. Chromatographic separation was performed on Phenomenex Synergi Polar-RP (30 × 2 mm, 4 μm) column with a gradient mobile phase composition of acetonitrile and 5 mM ammonium formate for positive mode and 0.1% formic acid in both water and acetonitrile for negative mode. The flow rate and runtime were 1.0 mL/min and 3.5 min, respectively. Sample extraction was done by protein precipitation using acetonitrile, enabling a fast analysis. The calibration ranges from 0.1 to 100, 0.1 to 100, and 1 to 1000 ng/mL for simvastatin, ramipril, and atenolol using internal standard carbamazepine in positive mode, respectively, whereas it was 0.3-300 and 2-2000 ng/mL for hydrochlorothiazide and aspirin using internal standard 7-hydroxy coumarin in negative mode, respectively. Hansen solubility parameters can be used as a high-throughput optimizing tool for column and mobile phase selection in bioanalysis. This validated bioanalytical method has the potential for future fixed dose combination based preclinical and clinical studies that can save analysis time.
Collapse
Affiliation(s)
| | - Hanumanth Srikanth Cheruvu
- Biology Division, DMPK Laboratory, GVKBIO, Hyderabad, India.,Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hyderabad, India
| | | | | | - Sunitha Sampathi
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hyderabad, India
| | | |
Collapse
|
5
|
Burt T, John CS, Ruckle JL, Vuong LT. Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: a range of study methodologies and conduct considerations. Accelerating development of novel pharmaceuticals through safe testing in humans – a practical guide. Expert Opin Drug Deliv 2016; 14:657-672. [DOI: 10.1080/17425247.2016.1227786] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
6
|
Togashi K, Mutaguchi K, Komuro S, Kataoka M, Yamazaki H, Yamashita S. Systematic approach to optimize a pretreatment method for ultrasensitive liquid chromatography with tandem mass spectrometry analysis of multiple target compounds in biological samples. J Sep Sci 2016; 39:3212-20. [DOI: 10.1002/jssc.201600282] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2016] [Revised: 06/04/2016] [Accepted: 06/18/2016] [Indexed: 12/26/2022]
Affiliation(s)
- Kazutaka Togashi
- Pharmaceutical Division; Sumika Chemical Analysis Service Ltd; Osaka Japan
| | - Kuninori Mutaguchi
- Pharmaceutical Division; Sumika Chemical Analysis Service Ltd; Osaka Japan
| | - Setsuko Komuro
- Pharmaceutical Division; Sumika Chemical Analysis Service Ltd; Osaka Japan
| | - Makoto Kataoka
- Faculty of Pharmaceutical Sciences; Setsunan University; Hirakata Osaka Japan
| | - Hiroshi Yamazaki
- Laboratory of Drug Metabolism and Pharmacokinetics; Showa Pharmaceutical University; Tokyo Japan
| | - Shinji Yamashita
- Faculty of Pharmaceutical Sciences; Setsunan University; Hirakata Osaka Japan
| |
Collapse
|
7
|
Burt T, Yoshida K, Lappin G, Vuong L, John C, de Wildt SN, Sugiyama Y, Rowland M. Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development. Clin Transl Sci 2016; 9:74-88. [PMID: 26918865 PMCID: PMC5351314 DOI: 10.1111/cts.12390] [Citation(s) in RCA: 53] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2016] [Revised: 02/18/2016] [Accepted: 02/18/2016] [Indexed: 12/13/2022] Open
Affiliation(s)
- T Burt
- Principal, Burt Consultancy, Durham, NC, 27705, USA
| | - K Yoshida
- Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.,Oak Ridge Institution for Science and Education (ORISE) Fellow
| | - G Lappin
- Visiting Professor of Pharmacology School of Pharmacy University of Lincoln, Joseph Banks Laboratories, Lincoln, LN6 7DL, UK
| | - L Vuong
- Principal, LTV Consulting, Davis, CA, USA.,Clinical Advisor at BioCore, Seoul, South Korea
| | - C John
- Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA
| | - S N de Wildt
- Intensive Care and Pediatric Surgery, Erasmus MC Sophia Children's Hospital, Rotterdam, The Netherlands
| | - Y Sugiyama
- Sugiyama Laboratory, RIKEN Innovation Center, RIKEN, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan
| | - M Rowland
- Centre for Applied Pharmacokinetic Research, University of Manchester, Manchester, M13 9PT, UK.,Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, USA
| |
Collapse
|
8
|
Saleem K, Ali I, Kulsum U, Aboul-Enein HY. Recent developments in HPLC analysis of β-blockers in biological samples. J Chromatogr Sci 2013; 51:807-18. [PMID: 23619556 DOI: 10.1093/chromsci/bmt030] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
β-Adrenergic blockers represent a very important class of drugs that are used worldwide for treating various cardiac diseases. The present article describes the state-of-the art of analyses of β-adrenergic blockers using high-performance liquid chromatography (HPLC). Sample preparation techniques such as liquid-liquid extraction, solid-phase extraction and solid-phase microextraction have been discussed, which are essential prior to HPLC analysis. Additionally, applications of liquid chromatography coupled with tandem mass spectrometry are included. HPLC methods have been reported to include 0.6-26 min as the run times and 0.01 ng/mL to 25 µg/mL as detection limits. The most commonly used columns were C18 with various buffers as the mobile phases, along with various organic modifiers. The optimization of HPLC conditions has been discussed. It has been observed that the reported methods are quite satisfactory for the analyses of β-adrenergic blockers in biological samples. Future perspectives in the hyphenation of solid-phase microextraction-nano-liquid chromatography-tandem mass spectrometry have also been highlighted to achieve detections at nanogram and picogram levels. The present article is very useful for academicians, scientists, drug and pharmaceutical personnel and government regulatory authorities.
Collapse
Affiliation(s)
- Kishwar Saleem
- Department of Chemistry, Jamia Millia Islamia, Central University, New Delhi, India
| | | | | | | |
Collapse
|
9
|
Simultaneous estimation of amlodipine and atenolol in human plasma: a sensitive LC–MS/MS method validation and its application to a clinical PK study. Bioanalysis 2013; 5:827-37. [DOI: 10.4155/bio.13.39] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Background: A highly sensitive, specific and rapid LC–ESI-MS/MS method has been developed and validated for simultaneous quantification of amlodipine (AMD) and atenolol (ATL) in human plasma (200 µl) using AMD-d4 and ATL-d7, respectively, as an internal standard (IS) as per the regulatory guidelines. Results: The SPE method was used to extract the analytes and IS from human plasma. The chromatographic resolution of AMD, ATL and corresponding IS was achieved using an isocratic flow on a C18 column. The total chromatographic run time was 3 min. A linear response function was established for the range of concentrations 50–8000 pg/ml and 10–800 ng/ml for AMD and ATL, respectively, in human plasma. Conclusion: The intra- and inter-day accuracy and precision values for AMD and ATL met the acceptance as per regulatory guidelines. The validated assay was applied to a fixed-dose combination of AMD and ATL (Adopin-AT®) PK study in humans.
Collapse
|
10
|
Cho DY, Bae SH, Shon JH, Bae SK. High-sensitive LC-MS/MS method for the simultaneous determination of mirodenafil and its major metabolite, SK-3541, in human plasma: Application to microdose clinical trials of mirodenafil. J Sep Sci 2013; 36:840-8. [DOI: 10.1002/jssc.201200919] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2012] [Revised: 11/01/2012] [Accepted: 11/08/2012] [Indexed: 11/08/2022]
Affiliation(s)
- Doo-Yeoun Cho
- Department of Family Practice & Community Health; Ajou University School of Medicine; Suwon Korea
| | - Soo Hyeon Bae
- College of Pharmacy; The Catholic University of Korea; Bucheon Korea
| | - Ji-Hong Shon
- Department of Clinical Pharmacology and Clinical Trial Center; Inje University Busan Paik Hospital; Busan Korea
| | - Soo Kyung Bae
- College of Pharmacy; The Catholic University of Korea; Bucheon Korea
| |
Collapse
|
11
|
Sun L, Li H, Willson K, Breidinger S, Rizk ML, Wenning L, Woolf EJ. Ultrasensitive Liquid Chromatography–Tandem Mass Spectrometric Methodologies for Quantification of Five HIV-1 Integrase Inhibitors in Plasma for a Microdose Clinical Trial. Anal Chem 2012; 84:8614-21. [PMID: 23030780 DOI: 10.1021/ac301581h] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Li Sun
- Merck Research Laboratories,
West Point, Pennsylvania, 19486, United States
| | - Hankun Li
- Merck Research Laboratories,
West Point, Pennsylvania, 19486, United States
| | - Kenneth Willson
- Merck Research Laboratories,
West Point, Pennsylvania, 19486, United States
| | - Sheila Breidinger
- Merck Research Laboratories,
West Point, Pennsylvania, 19486, United States
| | - Matthew L. Rizk
- Merck Research Laboratories,
West Point, Pennsylvania, 19486, United States
| | - Larissa Wenning
- Merck Research Laboratories,
West Point, Pennsylvania, 19486, United States
| | - Eric J. Woolf
- Merck Research Laboratories,
West Point, Pennsylvania, 19486, United States
| |
Collapse
|
12
|
Determination of celiprolol in human plasma using high performance liquid chromatography with fluorescence detection for clinical application. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 904:88-92. [DOI: 10.1016/j.jchromb.2012.07.026] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2012] [Revised: 07/04/2012] [Accepted: 07/24/2012] [Indexed: 12/15/2022]
|
13
|
Kallem RR, Inamadugu JK, Ramesh M, Seshagirirao JVLN. Sensitive LC-MS/MS-ESI method for simultaneous determination of nifedipine and atenolol in human plasma and its application to a human pharmacokinetic study. Biomed Chromatogr 2012; 27:349-55. [DOI: 10.1002/bmc.2798] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2012] [Accepted: 07/03/2012] [Indexed: 11/08/2022]
Affiliation(s)
- Raja Reddy Kallem
- College of Pharmaceutical Sciences; Andhra University; Visakhapatnam-530 003 A.P. India
| | | | - Mullangi Ramesh
- Jubilant Biosys, 2 Stage; Industrial Suburb; Yeshwanthpur Bangalore-560 022 India
| | | |
Collapse
|